Myth-buster
B vitamins lowered homocysteine by 2.36 µmol/L in heart patients — but didn't reduce heart attacks or deaths.
This meta-analysis confirms that combined B9, B6, and B12 supplementation reliably drops homocysteine, yet that lab improvement didn't translate into fewer major cardiovascular events — a reminder that a biomarker win isn't always a clinical win.
In a meta-analysis of 539 coronary heart disease patients, combined B-vitamin supplements (folic acid, B6, B12) lowered homocysteine levels by an average of 2.36 units — a statistically significant drop. However, the same analysis found no reduction in major cardiovascular events or cardiovascular mortality, meaning the benefit was limited to a lab value and a reduction in artery re-narrowing (restenosis), not to the outcomes that matter most to patients.
Where this fits in the evidence
Pillser has synthesized 7 studies on Vitamin B9 for Reduced Homocysteine Level — overall evidence strength: High.
Across 7 studies, 6 reported beneficial effects of Vitamin B9 supplementation on reducing homocysteine levels, with a predominant effect size ranging from small to moderate. Most evidence comes from randomized controlled trials and meta-analyses in clinical populations (e.g., coronary heart disease, type 2 diabetes) and healthy adults, with doses typically around 1 mg/day and effects observed at 8–12 weeks. The median study duration was 84 days, indicating sustained supplementation is typical for achieving reductions.
The study
- Meta-Analysis
- n = 539
- 2026-01-30
- Annals of medicine
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.